Bibliographic
Brevetti EPO No.2943185 2020.11.18
Brevetti EPO
(10) Registration Number and Date
2021000091 2021.02.23
Status
Registered
(180) Expiration Date
(20) Filing Number and Date
SM /T/2021/000091 2014.01.09
(40) Publication Number and Date
SM /T/2021/000091 2021.02.23
(30) Priority Details
US 201361750797 P
2013.01.09
US 201361762833 P
2013.02.08
(51) IPC Classes
(71/73) Applicant
(IT) EDGEMONT PHARMACEUTICALS LLC LIQUIDATING TRUST : 1037 Raymond Blvd., Suite 1520, 07102 Newark NJ, US
(72) Inventor
(IT) SALTEL, Douglas A. : c/o Edgemont Pharmaceuticals1250 Capital of Texas HwySouth Building 3Suite 400, Austin, Texas 78746, US
(IT) VACHON, Michael : c/o Edgemont Pharmaceuticals1250 Capital of Texas HwySouth Building 3Suite 400, Austin, Texas 78746, US
(74) Representative Name
(IT) FERRIERO, Paolo : Via Consiglio dei Sessanta, 99, 47891 Dogana RSM, SM
(54) Title
(IT) FORMULAZIONI A RILASCIO PROLUNGATO DI LORAZEPAM
(EN) SUSTAINED RELEASE FORMULATIONS OF LORAZEPAM
(57) Abstract
(58) Citations
Document
Document Type Date Action
Traduzione 2021.03.18
Event
Event NameDateStatus
Filing2014.01.09Filed
Brevetto EPO concesso2021.02.23Published
Ricevuta pagamento annualita 82021.02.24Payed
Ricevuta pagamento annualita 92021.12.23Payed
Ricevuta pagamento annualita 102022.12.20Payed
Ricevuta pagamento annualita 112023.12.18Payed
Ricevuta pagamento annualita 122025.01.30Payed
Description
Claims